Evidence map›Paper›PMID 33269990›Full record

ArticleHuman vaccines & immunotherapeutics2021

Modeling the epidemiological impact and cost-effectiveness of a combined schoolgirl HPV vaccination and cervical cancer screening program among Chinese women.

Xiaomeng Ma, Katherine Harripersaud, Kumi Smith, Christopher K Fairley, Huachun Zou, Zhuoru Zou, Yueyun Wang, Guihua Zhuang, Lei Zhang

Open access · greenAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

Xiaomeng MaChina-Australia Joint Research Center for Infectious Diseases, School of Public Health, Health Science Centre, Xi'an Jiao Tong University, Xi'an, China.ORCID 0000-0002-4165-3062
Katherine HarripersaudDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
Kumi SmithDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
Christopher K FairleyMelbourne Sexual Health Centre, Alfred Health, Carlton, Australia.ORCID 0000-0001-9081-1664
Huachun ZouSchool of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, China.
Zhuoru ZouChina-Australia Joint Research Center for Infectious Diseases, School of Public Health, Health Science Centre, Xi'an Jiao Tong University, Xi'an, China.ORCID 0000-0001-8837-0900
Yueyun WangDepartment of Maternal Care, Shenzhen Maternity and Child Health Hospitals, Shenzhen, Guangdong, China.
Guihua ZhuangChina-Australia Joint Research Center for Infectious Diseases, School of Public Health, Health Science Centre, Xi'an Jiao Tong University, Xi'an, China.
Lei ZhangChina-Australia Joint Research Center for Infectious Diseases, School of Public Health, Health Science Centre, Xi'an Jiao Tong University, Xi'an, China.ORCID 0000-0003-2343-084X
Melbourne Sexual Health Centre · AUUniversity of Minnesota · USXi'an Jiaotong University · CNShenzhen Maternity and Child Healthcare Hospital · CNSun Yat-sen University · CNUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human papillomavirus (HPV) infection is common in women and also the main cause of cervical cancer. Based on a dynamic compartmental model, we aimed to evaluate the population impact and cost-effectiveness of strategies that combined cervical cancer screening and HPV schoolgirl vaccination for Chinese women. The effectiveness of interventions was assessed by comparing modeled scenarios to the status quo, where a 3-y cervical cancer screening program remained at a 20% coverage and without a universal HPV vaccination program. Our study demonstrated that increasing screening coverage from 20% to 50% would reduce the high-risk HPV (HR-HPV) prevalence to 5.4%, whereas a universal schoolgirl vaccination program using the quadrivalent vaccine (qHPV) with a coverage of 50% would reduce the prevalence to 2.9% by 2069. Scaling-up the cervical screening coverage to 50% will prevent 16,012 (95% CI: 8,791 to 25,913) Disability-Adjusted Life-Years (DALYs) per year, with an incremental cost-effectiveness ratio (ICER) of US$ 10,958 (95% CI: $169 to $26,973)/DALY prevented. At the current qHPV price, vaccinating 50% of school girls will prevent 13,854 (95% CI: 8,355 to 20,776) DALYs/year, but the corresponding incremental cost-effectiveness ratio (ICER, US$ 83,043, 95% CI: $52,234 to $138,025) exceeds cost-effectiveness threshold (i.e., 3 times GDP per-capita of China: $30,792). The qHPV vaccine requires at least a 50% price reduction to be cost-effective. Vaccinating schoolgirls will result in a large population health benefit in the long term, but such a universal HPV vaccination program can only be cost-effective with a substantial price reduction.

Indexed as

Papillomavirus InfectionsPapillomavirus VaccinesUterine Cervical NeoplasmsChinaCost-Benefit AnalysisEarly Detection of CancerFemaleHumansQuality-Adjusted Life YearsVaccinationPapillomavirus Vaccinescervical cancercost-effectivenesseconomic evaluationHuman papillomavirusinterventionscreeningvaccination

Identifiers

PMID33269990
PMCPMC8018426
OpenAlexW3109680238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.